Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Ali

Vascular & Interventional Radiology Mishawaka, IN Medical Doctor

NPI 1679759898 CMS profile 302925

250 E Day Rd Ste 300, Mishawaka, IN 46545

Open in the dashboard

General payments

$10,863

262 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Ali of Mishawaka, IN is reported in the CMS Open Payments database as having received $10,863 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,794 61
2024 General $1,432 51
2023 General $3,216 74
2022 General $1,134 31
2021 General $445 19
2020 General $360 10
2019 General $482 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Ali
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Mohammad Ali were reported at $3,794. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Mohammad Ali Vascular & Interventional Radiology median Middle half National median
2019 $482 $422 $125–$1,555 $163
2020 $360 $200 $68–$652 $114
2021 $445 $280 $99–$866 $132
2022 $1,134 $433 $137–$1,497 $149
2023 $3,216 $506 $152–$2,019 $160
2024 $1,432 $556 $175–$1,930 $164
2025 $3,794 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,358 57 payments
  2. Penumbra, Inc. $1,953 7 payments
  3. Inari Medical, Inc. $1,061 92 payments
  4. Medtronic, Inc. $700 18 payments
  5. Terumo Medical Corporation $607 13 payments
  6. Bard Peripheral Vascular, Inc. $524 7 payments
  7. Stryker Corporation $514 14 payments
  8. Shockwave Medical, Inc $348 5 payments
  9. Sirtex Medical Inc $335 5 payments
  10. Siemens Medical Solutions USA, Inc. $288 12 payments
  11. Other $1,173 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,438 254 payments
  2. Travel and Lodging $2,425 8 payments
Products named General payments · program years 2019–2025
  1. Indigo System $1,953 7 payments
  2. SpyGlass Discover $1,551 7 payments
  3. FLOWTRIEVER CATHETER, S $1,110 95 payments
  4. CT THROMBECTOMY SYSTEM KIT $1,082 93 payments
  5. Azur CX Detachable $619 8 payments
  6. CONCERTOTM $357 8 payments
  7. ARTIX MT $326 5 payments
  8. HydroPearl $291 5 payments
  9. TheraSphere Y90 Glass Microspheres 10 GBq $279 2 payments
  10. ANGIOJET $261 3 payments
  11. Other $4,445 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

23

Median for Interventional Radiology: 38

Drug cost

$188

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $96
Ondansetron Odt Ondansetron Brand 11 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 126 billing codes

Paid by Medicare

$88,873

Medicare's payments for the services billed

Medicare patients

470

Average age 72

Services billed

1,149

219 women, 251 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Arthritis 51%
Diabetes 50%
Heart failure 45%
Ischemic heart disease 42%
COPD 32%
Cancer 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record